RNS Number : 4430F
Redx Pharma plc
07 November 2022

REDX PHARMA PLC
("Redx" or "the Company")

Redx to Present on the Potential of RXC007 in Fibrotic Diseases at the Antifibrotic Drug Discovery Meeting

Alderley Park, UK, 7 November 2022 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that Dr Nicolas Guisot, VP, Drug Discovery at Redx Pharma, will speak at the Antifibrotic Drug Discovery (AFDD) Meeting (9-11 November 2022, Boston, MA) and present a poster on the Company's lead fibrosis asset, RXC007.

In the presentation, which will take place on Friday 11 November at 09:30 am (EST), Dr Guisot will discuss RXC007, focusing on selective Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibition in lung fibrosis, other fibrotic diseases and in cancer- associated fibrosis.

In addition to Dr Guisot's presentation, Redx will present a poster at the AFDD Meeting on Thursday 10 November at 3:00 pm (EST), which details the potential of RXC007 in the treatment of fibrosis, including for idiopathic pulmonary fibrosis (IPF) and chronic fibrosing interstitial lung disease (CF-ILD), where there is robust preclinical efficacy data across disease models supporting clinical development in these areas.

RXC007 is a highly potent, selective and orally-active ROCK2 inhibitor targeting multiple diseases associated with fibrosis, being developed for interstitial lung disease, including IPF. A Phase 2a study assessing RXC007 as a potential treatment for patients with IPF began in October 2022, with headline data anticipated to be available in H2 2023.

Details of the poster presentation are as follows:

Title:	**Potential of RXC007, a highly selective Rho-Associated Coiled Kinase 2 (ROCK2) inhibitor to tackle fibrotic lung disease**
Day/Date:	Thursday 10 November 2022
Time:	15.00 EST

A copy of the poster will be made available on the Company's website following the presentation at: https://www.redxpharma.com/scientific-publications/

For further information, please contact:

Redx Pharma Plc T: +44 (0)1625 469 918
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com

Lisa Anson, Chief Executive Officer

US Office
Peter Collum, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550
Matt Davis/ Adam Dawes

WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330
Claes SpŒng/ Satheesh Nadarajah/ David Wilson

Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886 2500
Rupert Dearden/ Freddy Crossley/ Emma Earl

FTI Consulting T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-dependent cancers, commenced a Phase 2 programme in November 2021. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a preclinical pan-RAF inhibitor which has received IND clearance from the US FDA, and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

END

NRABRBDBLUGDGDS